22nd February 2021
Diaprost announced today a publication in the journal of Clinical Cancer Research on PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates.
The extensive preclinical study was conducted at Memorial Sloan Kettering Cancer Center (MSK) on Diaprost’s propriety antibody (hu5A10) targeting PSA. This rigorous preclinical evaluation of radiolabeled hu5A10-based compounds in prostate cancer (PCa) mouse models and non-human primates, establishes hu5A10 as a promising theranostic (therapy and diagnostic) agent that allows specific and effective delivery of radionuclides to androgen receptor driven prostate tissue. The reported data strongly supports Diaprost’s planned efforts to translate h5A10 to patients.
Press Release Diaprost February 22, 2021
Pressmeddelande Diaprost 22 februari, 2021
25th August 2020
Diaprost announced today that it has signed an exclusive license agreement with Memorial Sloan Kettering Cancer Center for IP related to the use of PSA antibodies for therapeutic and diagnostic purposes for prostate cancer.
Press release Diaprost August 25
Pressmeddelande Diaprost 25 augusti
21st January 2020
Diaprost entered into an exclusive Research and Option Agreement with a Top 10 Pharmaceutical company strategic partner in October 2017. Diaprost now announces that its strategic partner has exercised its option to acquire rights to its h11B6 antibody.
Press release Diaprost jan 21 2020
4th October 2017
Diaprost have agreed terms for an exclusive Research and Option Agreement, inclusive of an upfront payment, research funding and potential development milestone payments for its h11B6 antibody for prostate cancer.
Pressmeddelande Diaprost 4 okt 2017
Press release Diaprost oct 4 2017
13th December 2016
A new publication in Science Translational Medicine demonstrates that in vivo targeting of the enzyme human kallikrein-related peptidase 2 (hK2) is a powerful tool that can be used for detection of prostate cancer and monitoring treatment by quantifying the activity of the androgen receptor pathway.
Pressmeddelande Diaprost 13 dec 2016
Press release Diaprost dec 13 2016